Xiuqi Liang

748 citations
20 papers · 545 indexed · h-index 14
Topics
Nanoplatforms for cancer theranostics (10 papers)Immunotherapy and Immune Responses (9 papers)Immune cells in cancer (6 papers)

In The Last Decade

Xiuqi Liang

20 papers receiving 538 citations

Peers

Xiuqi Liang
Comparison fields: 5 of 71
  • Biomedical Engineering 284
  • Molecular Biology 201
  • Immunology 175
  • Biomaterials 132
  • Materials Chemistry 96
Replace Zhenwei Su with:
Zhenwei Su China
Zijian Xiong China
Lihuan Shang China
Feiyang Jin China
Le Minh Pham South Korea
Suleixin Yang China
Sooseok Im South Korea
Xuechao Jin China
Candido G. Da Silva Netherlands
Fengyun Shen China
Xiuqi Liang relative to Zhenwei Su China Zhenwei Su's profile →
Citations per field
00.5×
Zhenwei Su · 1×
Citations per year

Countries citing papers authored by Xiuqi Liang

Since Specialization
Citations

This map shows the geographic impact of Xiuqi Liang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiuqi Liang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiuqi Liang more than expected).

Fields of papers citing papers by Xiuqi Liang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiuqi Liang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiuqi Liang. The network helps show where Xiuqi Liang may publish in the future.

Co-authorship network of co-authors of Xiuqi Liang

This figure shows the co-authorship network connecting the top 25 collaborators of Xiuqi Liang. A scholar is included among the top collaborators of Xiuqi Liang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiuqi Liang. Xiuqi Liang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 7
2 6
3 3
4 13
5 15
6 3
7 17
8 41
9 65
10 14
11 35
12 52
13 62
14 31
15 39
16 74
17 26
18 37
19
[Antitumor effect of gene gun-mediated DNA vaccine pWRG-neu immunization in C57BL/6 mice].
3
20
[The use of gene gun in cancer gene therapy].
2

About Xiuqi Liang

Xiuqi Liang is a scholar working on Immunology, Biotechnology and Biomedical Engineering, having authored 20 papers that have together received 545 indexed citations. Recurring topics across this work include Nanoplatforms for cancer theranostics (10 papers), Immunotherapy and Immune Responses (9 papers) and Immune cells in cancer (6 papers). The work is most often cited by research in Biomaterials (132 citations), Immunology (175 citations) and Biomedical Engineering (284 citations). Xiuqi Liang has collaborated with scholars based in China, Singapore and United States. Frequent co-authors include Changyang Gong, Qinjie Wu, Xinchao Li, Tao He, Lu Li, Shunyao Zhu, Meiling Shen, Tao He, Rui Luo and Linjiang Song. Their work appears in journals such as Journal of the American Chemical Society, Biomaterials and Chemical Engineering Journal.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026